In Setback For Glaxo, European Court Clears Paxil Generics

Law360, New York (January 20, 2005, 12:00 AM EST) -- In a blow to U.K. drug maker GlaxoSmithKline PLC, the European Court of Justice has ruled that generic drug makers should be allowed to market versions of its top-selling anti-depressant Seroxat, marketed in the U.S. as Paxil.

The appeals court upheld a ruling by Danish authorities to approve generic drugs based on the active ingredients in Paxil, known in Europe as Seroxat.

Glaxo had appealed the Danish ruling, arguing that the generic drug makers were using "a different salt form" of Paxil's active ingredient and should...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.